Shibasaki Seiji, Ueda Mitsuyoshi
General Education Center, Graduate School of Pharmacy, Hyogo University of Health Sciences, 1-3-6 Minatojima, Chuo-ku, Kobe, 650-8530, Japan.
Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Kitashirakawa-oiwakecho, Sakyo-ku, Kyoto, 606-8502, Japan.
Methods Mol Biol. 2017;1625:237-245. doi: 10.1007/978-1-4939-7104-6_16.
In recent years, genetic engineering and protein expression technologies have promoted the development of recombinant protein vaccines. To accelerate the development of efficient vaccines for mycosis, screening candidate antigens, and determining the optimal route of administration are indispensable steps. Two methods for identifying novel antigens and producing antigens specific to Candida albicans, as a model causative pathogen of mycosis, are discussed in this chapter. Specifically, the application of liquid chromatography/tandem mass spectrometry using a long monolithic column for proteome analysis to identify virulence factors of C. albicans, followed by molecular display technology to produce an oral vaccine using antigens found by the proteomic study, is described.
近年来，基因工程和蛋白质表达技术推动了重组蛋白疫苗的发展。为加速开发针对真菌病的高效疫苗，筛选候选抗原以及确定最佳给药途径是必不可少的步骤。本章讨论了两种鉴定新型抗原以及生产针对白色念珠菌（作为真菌病的典型致病病原体）的特异性抗原的方法。具体而言，描述了使用长整体柱进行蛋白质组分析的液相色谱/串联质谱法来鉴定白色念珠菌的毒力因子，随后利用分子展示技术，使用蛋白质组学研究中发现的抗原生产口服疫苗。
